Prognostic Biomarker Found for Colon Cancer Patients
|
By LabMedica International staff writers Posted on 10 Feb 2016 |

Image: Patients whose stage II colon cancer tested negative for CDX2 expression (left) had a worse prognosis than those whose cancer tested positive (right) (Photo courtesy of Columbia University Medical Center).
The majority of colon cancer patients whose tumors have started to travel to nearby tissue but no further are cured by surgery alone, but in a minority of these stage II colon cancer cases the cancer returns and the patients die.
The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery and microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice.
Scientists at the Columbia University Medical Center (New York, NY, USA) and their colleagues obtained colon-cancer tissue microarrays, fully annotated with clinical and pathological information, from three independent sources: 367 patients in the Cancer Diagnosis Program of the National Cancer Institute, 1,519 patients in the National Surgical Adjuvant Breast and Bowel Project C-07 trial, and 321 patients in the Stanford Tissue Microarray Database.
Formalin-fixed, paraffin-embedded tissue sections were stained with a mouse antihuman caudal-type homeobox transcription factor 2 (CDX2) monoclonal antibody that was previously validated for diagnostic applications (clone CDX2-88, BioGenex; Fremont, CA, USA). Tissue slides were stained on a Bond-Max automatic stainer and antigen detection was visualized with the use of the Bond Polymer Refine Detection kit (Leica Microsystems; Buffalo Grove, IL, USA). All tissue microarrays were scored for CDX2 expression in a blinded fashion and in cases in which tissue microarrays contained two tissue cores for a patient the two cores were scored independently and paired at the end.
Using a new bioinformatics approach, the team searched data from over 2,000 colon cancer patients and found 16 genes whose lack of expression is always tied to high levels of cancer stem cell markers. Of the 16 potential biomarkers, they found only one, the gene CDX2, for which a standardized test that detects its expression is already available. CDX2 regulates cell differentiation that is deciding the type of cell an immature stem cell matures into in the lining of the colon, which is where colon cancer starts. The team found that colon cancer patients whose tumors did not express CDX2 were more likely to relapse and die compared with patients whose tumors did express CDX2.
Piero Dalerba, MD, an assistant professor of medicine, pathology and cell biology, and lead author said, “We wanted to understand if the small group lacking CDX2 expression—approximately 4% of the global colon cancer population—fared poorly because of an intrinsic resistance to chemotherapy. To our surprise, we found that, on the contrary, tumors lacking CDX2 expression, despite being very aggressive from a biological point of view, also appeared to benefit from early treatment with adjuvant chemotherapy.” The study was published on January 21, 2016, in the New England Journal of Medicine (NEJM).
Related Links:
Columbia University Medical Center
BioGenex
Leica Microsystems
The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery and microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice.
Scientists at the Columbia University Medical Center (New York, NY, USA) and their colleagues obtained colon-cancer tissue microarrays, fully annotated with clinical and pathological information, from three independent sources: 367 patients in the Cancer Diagnosis Program of the National Cancer Institute, 1,519 patients in the National Surgical Adjuvant Breast and Bowel Project C-07 trial, and 321 patients in the Stanford Tissue Microarray Database.
Formalin-fixed, paraffin-embedded tissue sections were stained with a mouse antihuman caudal-type homeobox transcription factor 2 (CDX2) monoclonal antibody that was previously validated for diagnostic applications (clone CDX2-88, BioGenex; Fremont, CA, USA). Tissue slides were stained on a Bond-Max automatic stainer and antigen detection was visualized with the use of the Bond Polymer Refine Detection kit (Leica Microsystems; Buffalo Grove, IL, USA). All tissue microarrays were scored for CDX2 expression in a blinded fashion and in cases in which tissue microarrays contained two tissue cores for a patient the two cores were scored independently and paired at the end.
Using a new bioinformatics approach, the team searched data from over 2,000 colon cancer patients and found 16 genes whose lack of expression is always tied to high levels of cancer stem cell markers. Of the 16 potential biomarkers, they found only one, the gene CDX2, for which a standardized test that detects its expression is already available. CDX2 regulates cell differentiation that is deciding the type of cell an immature stem cell matures into in the lining of the colon, which is where colon cancer starts. The team found that colon cancer patients whose tumors did not express CDX2 were more likely to relapse and die compared with patients whose tumors did express CDX2.
Piero Dalerba, MD, an assistant professor of medicine, pathology and cell biology, and lead author said, “We wanted to understand if the small group lacking CDX2 expression—approximately 4% of the global colon cancer population—fared poorly because of an intrinsic resistance to chemotherapy. To our surprise, we found that, on the contrary, tumors lacking CDX2 expression, despite being very aggressive from a biological point of view, also appeared to benefit from early treatment with adjuvant chemotherapy.” The study was published on January 21, 2016, in the New England Journal of Medicine (NEJM).
Related Links:
Columbia University Medical Center
BioGenex
Leica Microsystems
Latest Molecular Diagnostics News
- Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
- Genome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
- Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







